MWNA
OXFD

Marshall Wace North America’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Marshall Wace North America’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24,556
Closed -$287K – 1713
2020
Q3 		$287K Buy
+24,556
New +$326K ﹤0.01% 1075
2018
Q3 		– Sell
-69,663
Closed -$898K – 1551
2018
Q2 		$898K Buy
+69,663
New +$941K 0.01% 957

Other funds holding OXFD

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace North America's OXFD Position: Q4 2020 in Review

Marshall Wace North America sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q4 2020, closing a stake of 24,556 shares — an estimated $287K sold.

Marshall Wace North America first reported a position in OXFD in Q2 2018 and held it in 2 quarters. The position peaked at $898K in Q2 2018. 60 funds tracked by Wall St. Rank hold OXFD as of Q4 2020.

  • Marshall Wace North America reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 24,556 Oxford Immunotec Global PLC Ordinary Shares shares in Q4 2020, an estimated $287K.
  • Marshall Wace North America first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q2 2018 and held it in 2 quarters.
  • Marshall Wace North America's Oxford Immunotec Global PLC Ordinary Shares position peaked at $898K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.